SUMMARY We report a randomised double blind trial of myo-inositol (inositol) supplementation for 10 days in 74 preterm infants with a birth weight less than 2000 g (mean gestational age 29-5 weeks and mean birth weight 1266 g). All infants required artificial ventilation for treatment of respiratory distress syndrome. Inositol (120-160 mg/kg/day) was administered by the ingastric or intravenous route. The 37 infants who received inositol supplementation required less mechanical ventilation during days 4-10, had less failures of indomethacin to close ductus arteriosus, and had less deaths or bronchopulmonary dysplasia, or both, than the infants treated with placebo. There were no detectable adverse effects. These preliminary results suggest that inositol is an important nutrient in immature preterm infants.
Myo-inositol (inositol), a six carbon sugar alcohol, is at least as abundant as glucose in the body. In adults virtually all inositol is intracellular, whereas fetuses and immature preterm infants may also have high concentrations of inositol in serum.1-3 Inositol is a precursor of phosphoinositides. These phospholipids are membrane components and may serve, for instance, as a putative neurotransmitter, as 'tertiary' messengers of several hormones, and as a growth factor. 4 Although rodents on an inositol deficient diet may develop skin,5 gastrointestinal,6 and hepatic7 disturbances, dietary inositol requirements have not been established.8 The observation that inositol is synthesised in any tissue and is taken up into intracellular space by active transport has led to a limited nutritional interest in this compound.
Recently, it was found that an excess of inositol potentiates the glucocorticoid induced acceleration of the differentiation of lung surfactant.9 As critically ill newborn are deprived of breast milk rich in inositol, resulting in a decrease in serum inositol,?'"1 it was prudent to test whether exogenous inositol influenced the respiratory course in severe respiratory distress syndrome (RDS). The rationale of the study was to provide an intake of inositol similar to that in full breast feedings. The present report deals with a randomised double blind pilot study that evaluates the influence of inositol in treatment of RDS.
Patients and methods
Clinical methods. Study population The study was conducted in our hospital between January 1983 and August 1985. Preterm infants had to fulfil the following criteria to be included in the study:
(1) Birth weight <2000 g. (4) No other cardiopulmonary disease, mal- formation, or sepsis at birth or fetal hydrops. RDS was diagnosed on the basis of the following criteria:
(1) Symptoms and findings of respiratory distress (tachypnoea, retractions, grunting, apnoea, or extra oxygen required) for at least 72 hours from birth. (2) Chest x ray film compatible with RDS." (3) Low lecithin:sphingomyelin ratio and undetectable phosphatidylglycerol in tracheal aspirate during the first 24 hours. The lung effluent was obtained shortly after intubation during routine suctioning of the airways.
Normal saline (1-2 ml) was injected through the endotracheal tube. After a short hand ventilation any fluid that was recovered during suctioning of the airways (1 cm distal to the tip of the endotracheal tube) was collected into a Leuken's trap. The phospholipids were analysed using two dimensional thin layer chromatography. '2 Administration of sugars Infants were randomly and blindly assigned to be treated with inositol or placebo (glucose) after their parents had consented to their participation. Each set of solutions, containing either inositol or glucose (5% weight/volume each) had a code number. Only the pharmacist preparing the doses knew the contents of the drug packages. The sugars were given intragastrically shortly before gavage feedings in a dose of 160 mg/kg/day, divided into four doses. When all oral feeds were withheld the sugars were given intravenously. Based on a study of bioavailability (manuscript in preparation) the intravenous dose given was 75% of the intragastric one. All sugars were stored at -20°C and were discarded with 24 hours of use. The sugars were started at 12-48 hours of age and continued until 10 days. Contraindications for entry into the trial and indications for stopping the administration of sugars were low urine output (<1 ml/kg/h) or raised blood urea concentrations (> 8-3 mmol/l (50 mg/100 ml)), or both.
General management of infants
The indications for intubation and ventilation were apnoea at birth that did not respond to mask ventilation, requirement of > 60% oxygen, or failure to maintain arterial carbon dioxide tension below 70 mm Hg. Assisted ventilation was provided by a Baby Bird infant ventilator, using intermittent mandatory ventilation or continuous positive airway pressure. In general initial ventilator rates were 20-40/min, inspiratory time 0.8-1.0 seconds, peak inspiratory pressure 15-20 cm H2O, and positive end expiratory pressure 2-5 cm H20. Peak inspiratory pressure was increased when fractional inspiratory oxygen requirements were higher than 0-8.
Occasionally, when the conventional technique failed, infants were ventilated at a rate of 50-70/min. When the fractional inspiratory oxygen required was below 0-8, peak inspiratory pressure and ventilator rate were decreased. Small preterm infants were extubated when they required fractional inspiratory oxygen <0-3, positive end expiratory pressure <3 cm H20, and ventilator rates <4/min, whereas infants weighing > 1500 g were given continuous positive airway pressure before extubation. Apnoea of prematurity was treated with theophylline.
All infants had transcutaneous oxygen monitoring when fractional inspiratory oxygen was > 0-3. recorded at 1 (SD 0.5), 12 (SD 2), and 24 (SD 2) hours and thereafter at intervals of 24 hours until the age of 10 days.
The clinical diagnosis of bronchopulmonary dysplasia was made on the basis of two criteria.
(1) Respiratory distress and supplemental oxygen required for longer than 28 days.
(2) Persistent strands of densities in both lungs, alternating with areas of normal or increased lucency, or Northway radiographic stage 34.15
Cranial ultrasound scans were obtained serially, and intracranial haemorrhages were classified using the grading scale of Papile et al. 16 Necrotising enterocolitis was diagnosed on the basis of clinical manifestations: abdominal x ray showing pneumatosis intestinalis and air in the portal circulation. The diagnosis of retrolental fibroplasia was based on ophthalmological examination at postconceptional ages of 9 and 13 months.
Statistical evaluation. Biomedical Computer Program (BMPD statistical software, University of California Press, Berkeley, California, United States) was used for statistical calculations.
As this was the first study to evaluate the effect of inositol in the newborn and the animal studies were not relevant in terms of estimating the magnitude of any effect we elected at the beginning of the trial to examine the data when between 25 and 28 new patients were enrolled, to test whether continuing the study was justified. The present report represents the third interim analysis.
According to experimental data inositol accelerates synthesis of surfactant in the immature lung. It was therefore prudent to adopt outcome criteria that were similar to those used in surfactant substitution trials. Accordingly, the major outcome was categorised in two groups: (1) 'Intact' survival-that is, survival without bronchopulmonary dysplasia; (2) death or bronchopulmonary dysplasia, or both. According to analysis of our results during the years 1980-82 the occurrence of 'intact' survival was 50% in ventilated infants with RDS and birth weight less than 2000 g. We chose to limit the total number of infants to a maximum of 150-that is, enough to detect a 36% decline in the undesired outcome, assuming a type 1 error of 5% and a type 2 error of 10% .17
Outcome is affected by a number of prenatal and neonatal variables, and the treatment and control groups could have been accidentally unequal in terms of major prognostic variables. We therefore examined 63 prenatal and neonatal variables obtained from the medical charts. Multiple regression analysis was used to test whether some of the variables that tended to be different between the two groups actually affected the major outcome (BMDP 1R).
The initial severity of illness might have influenced the response to therapeutic intervention. We therefore adjusted for differences in severity in the groups treated with inositol or placebo using analysis of covariance (BMPD IV). Fractional inspiratory oxygen and mean airway pressure before treatment with the sugars was begun at 12 hours were chosen as the respective covariates. This model assumed that the chosen pretreatment variable was related to the treatment response and that the variables concerned were normally distributed. (Table 2) .
The two groups did not differ from each other in respect of fractional inspiratory oxygen, blood gases, or ventilatory measurements during the first 48 hours. Between days 4 and 10, however, the infants treated with inositol tended to have a milder respiratory course than the control infants. The infants treated with inositol tended to require less fractional inspiratory oxygen, although the difference was not significant. The a/A P02 ratio tended to be higher in infants treated with inositol than in control infants (Fig. 1) . Between days 4 and 8 the mean airway pressure was lower in infants in the inositol group than in the control group (BMDP IV, p<0-05; BMDP 4V, p<0-01). The ventilatory index tended to be significantly lower among the infants treated with inositol between days 4 and 7 (Fig. 2) . In addition, during days 8 to 10, fewer infants in the inositol group required mechanical ventilation than in the control group (p<005).
To analyse these differences further, the arterial blood gases and respirator settings were compared. Only the ventilator rates tended to be different (Fig. 3) . Infants in the inositol group required slower rates than the control infants during days 5 to 7 (p<002).
Fewer infants treated with inositol died or developed bronchopulmonary dysplasia compared with control infants (Table 3 ). The inositol group also had a tendency towards a lower incidence of pneumothorax and failure of indomethacin induced closure of patent ductus arteriosus. There was no detectable difference, however, in the incidence of intraventricular haemorrhage. Most of the babies died from RDS or bronchopulmonary dysplasia (Table 4) . Of the surviving infants with bronchopulmonary dysplasia, six required supplemental oxygen between 1 and 2 months (two in the inositol and four in the placebo group), five between 2 and 6 months (one in the inositol and four in the placebo group), and two more than 6 months (one in each group). Nine of the surviving infants with bronchopulmonary required mechanical ventilation after the neonatal period. All surviving infants are being followed up.
To assess whether the differences in the outcome were due to treatment with inositol rather than to confounding factors, multiple linear regression analyses were performed to assess the influence of some prenatal factors (gestational age, small for gestational age, single parent, bleeding, and mother on steroids) on the outcome. Only gestational age correlated significantly (p=0-05) with poor outcome (death or bronchopulmonary dysplasia, or both=0; good outcome= 1). Figure 4 shows outcome according to gestational age. 
Discussion
This randomised double blind trial involving preterm infants with RDS provides the first evidence that supplementation with inositol decreases the ventilatory needs and moderates the course of respiratory failure. In addition, there were fewer deaths or cases of bronchopulmonary dysplasia among the infants treated with inositol. The result may seem surprising because inositol had no immediate effects on ventilatory requirements or blood gases. In contrast, effective treatments of respiratory failure have had a direct, immediate effect on lung function, thus reversing the progressive course of respiratory failure, decreasing the incidence of severe complications, and reducing the number of infants who eventually developed bronchopulmonary dysplasia. Despite this, no infant with RDS died within 48 hours after beginning treatment with the sugar, and only two died before the sugar was given. The respiratory support was effective enough in most cases, therefore, to allow sufficient time (about 48 hours)9 for the effect of inositol to take place, and the study covered more than 90% of the population with RDS. The birthweight limit of less than 2000 g was chosen because the prognosis of RDS in this weight group is still poor, and oral feedings are often withheld. Although inositol prevents the synthesis of the second major surfactant component, phosphatidylglycerol, the paucity of this phospholipid in RDS is not a cause but a consequence of lung immaturity.19 20 According to current theory, inositol (inositol-phosphoinositide pair) augments the effect of glucocorticoid and thyroid hormone in the synthesis of surfactant phosphatidylcholine.9 Phosphatidylglycerol may have a similar function.9 21 The synthesis of phosphatidylglycerol in the immature lung is inactive, however, regardless of extracellular inositol concentration (Hallman M. Un-published observations.), whereas inositol is easily available for synthesis of surfactant phosphatidylinositol in immature alveolar cells, provided that the serum inositol concentration is high.2' 22 2 3 10 Mandatory withholding of the breast milk feedings from sick preterm infants decreased serum inositol concentrations sometimes below those present in the immature fetus,"( and low serum inositol concentrations in small preterm infants suffering from RDS were not associated with a favourable prognosis either.3 The aim of the present study, therefore, was to 'normalise' the intake of inositol and to find out whether inositol affects the natural history of RDS.
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